- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.07. | OS Therapies Inc - 8-K, Current Report | 4 | SEC Filings | ||
| 14.07. | OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer | 225 | Newsfile | Cash runway extended through 2026, beyond September 30, 2026 sunset date for rare pediatric priority review voucher (PRV) program Additional funding allows Company to advance strategic alternatives... ► Artikel lesen | |
| 10.07. | OS Therapies Provides Clinical & Global Regulatory Updates | 198 | Newsfile | End of Phase 2 Meeting with FDA scheduled for August 27, 2025 to review OST-HER2 recurrent, pulmonary metastatic osteosarcoma programScientific Advice Meetings confirmed with global regulators in major... ► Artikel lesen | |
| 03.07. | OS Therapies Shares Climb As FDA Grants End Of Phase 2 Meeting For OST-HER2 Program In Osteosarcoma | 1 | RTTNews | ||
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| 03.07. | OS Therapies granted FDA end of phase 2 meeting for osteosarcoma drug | 1 | Investing.com | ||
| 03.07. | OS Therapies erhält FDA-Treffen nach Phase 2 für Osteosarkom-Medikament | - | Investing.com Deutsch | ||
| 30.06. | OS Therapies reports positive survival data for osteosarcoma treatment | 1 | Investing.com | ||
| 24.06. | OS Therapies stock surges after positive FDA feedback on OST-HER2 | 1 | Investing.com | ||
| 24.06. | OS Therapies-Aktie steigt nach positiver FDA-Rückmeldung zu OST-HER2/n | 1 | Investing.com Deutsch | ||
| 24.06. | OS Therapies erhält positives FDA-Feedback für Osteosarkom-Behandlung | 1 | Investing.com Deutsch | ||
| 24.06. | OS Therapies receives positive FDA feedback for osteosarcoma treatment | 2 | Investing.com | ||
| 24.06. | OS Therapies Inc - 8-K, Current Report | 2 | SEC Filings | ||
| 11.06. | OS Therapies Taps EVERSANA To Launch First New Pediatric Osteosarcoma Treatment In 40 Years | 1 | RTTNews | ||
| 10.06. | OS Therapies kooperiert mit EVERSANA für Krebsmedikamenten-Markteinführung | 1 | Investing.com Deutsch | ||
| 06.06. | OS Therapies Submits Request For RMAT Designation For OST-HER2 | 1 | RTTNews | ||
| 06.06. | OS Therapies seeks FDA regenerative therapy tag for cancer drug | 1 | Investing.com | ||
| 23.05. | OS Therapies Inc - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 16.05. | OS Therapies GAAP EPS of -$0.18 misses by $0.11 | 2 | Seeking Alpha | ||
| 16.05. | OS Therapies Launches Subsidiary To Commercialize Canine Osteosarcoma Treatment | 1 | RTTNews | ||
| 07.05. | OS Therapies secures patent for cancer immunotherapy tech | 1 | Investing.com |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 58,00 | +3,57 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
| IMMUNIC | 0,834 | +0,60 % | EQS-News: Immunic AG: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Study/Study results
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,440 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort | -Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough, Massachusetts--(Newsfile Corp. -... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 9,576 | +1,31 % | Anavex Life Sciences files $300M common stock offering | ||
| ARCTURUS THERAPEUTICS | 13,505 | 0,00 % | EU Grants Marketing Authorization For KOSTAIVE To CSL And Arcturus Therapeutics | CANBERA (dpa-AFX) - Biotechnology firm CSL Ltd. (CSL.AX, CMXHF.PK) and sa-mRNA pioneer Arcturus Therapeutics Ltd. (ARCT) announced Friday that the European Commission has granted marketing authorization... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,270 | +1,60 % | Protalix BioTherapeutics Inc. Q1 Loss Narrows | JERUSALEM (dpa-AFX) - Protalix BioTherapeutics Inc. (PLX) released Loss for first quarter of -$3.62 millionThe company's earnings came in at -$3.62 million, or -$0.05 per share. This compares... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 10,400 | 0,00 % | Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism | CELEBRATION, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living... ► Artikel lesen | |
| GEOVAX LABS | 2,685 | -100,00 % | GeoVax Labs, Inc. - 8-K, Current Report | ||
| SCILEX | 8,810 | 0,00 % | Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule | PALO ALTO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing... ► Artikel lesen | |
| MEIRAGTX | 7,600 | +2,70 % | MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease | - This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease - RMAT designation includes the benefits... ► Artikel lesen | |
| TENAYA THERAPEUTICS | 0,870 | 0,00 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially... ► Artikel lesen | |
| INVIVYD | 0,746 | 0,00 % | Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection | Attractive safety profile demonstrated across all dosing cohorts and routes of administration (IV, SC, and IM); all reported adverse events (AEs) deemed unrelated or classified as mild to moderate... ► Artikel lesen | |
| UNICYCIVE THERAPEUTICS | 4,430 | 0,00 % | Unicycive Therapeutics, Inc.: Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement | LOS ALTOS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients... ► Artikel lesen | |
| NUVALENT | 83,40 | 0,00 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
| IMMUNOVANT | 17,910 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen |
Das Unternehmen OS THERAPIES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,675 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.